Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.33 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | DAO | P14920 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1610752 | 0.74 | TAAR1 (0.33) | L3MBTL1KDM4ETAAR1RAPGEF4 | |
| SCHEMBL18602124 | 0.72 | HTT (0.41) | SMN1; SMN2 | |
| SCHEMBL1610692 | 0.71 | TAAR1 (0.31) | TAAR1RAPGEF4 | |
| SCHEMBL598637 | 0.70 | KMT2A (0.41) | L3MBTL1KDM4ESMN1; SMN2RAPGEF4 | |
| SCHEMBL12802286 | 0.69 | GAA (0.36) | SMN1; SMN2TAAR1 | |
| SCHEMBL1611714 | 0.69 | TAAR1 (0.31) | TAAR1 | |
| SCHEMBL1610234 | 0.69 | TAAR1 (0.31) | TAAR1 | |
| SCHEMBL1610359 | 0.69 | KMT2A (0.32) | TAAR1 | |
| SCHEMBL395976 | 0.69 | KDM4E (0.35) | L3MBTL1KDM4EHSD17B10SMN1; SMN2TAAR1 | |
| SCHEMBL395487 | 0.69 | TAAR1 (0.40) | L3MBTL1KDM4EHIF1AHSD17B10TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170189389-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170189389-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | L3MBTL1 3601/4885KDM4E 4235/4885NUDT1 443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.